PortViewPortView
Immutep Limited logo

Immutep Limited (IMMP) Stock Analysis

NASDAQHealthcareBiotechnology

$3.39+7.62%
1-year price historyRange $3.10 – $63.60
52-week range$3.39
$3.05$70.60

Track IMMP in your portfolio for free · Portfolio tracker

What Immutep Limited does

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.

Key metrics

Market cap
$24.98M
P/E (TTM)
-0.47
EPS (TTM)
$-7.28
Beta
2.31
Dividend yield
0.00%
Revenue / share
$0.10
50-day avg
$5.54
200-day avg
$17.84
52-week high
$70.60
52-week low
$3.05
CEO
Marc Voigt

ETFs linked to IMMP

Broad-market and Healthcare sector ETFs an investor holding Immutep Limited is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how IMMP fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze IMMP in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Immutep Limited?
Immutep Limited trades under the ticker IMMP on NASDAQ.
Which exchange is IMMP listed on?
IMMP is listed on NASDAQ.
What sector does Immutep Limited operate in?
Immutep Limited is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze IMMP in a portfolio?
PortView shows IMMP's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.